Efficacy of high-dose meropenem (six grams per day) in treatment of experimental murine pneumonia induced by meropenem-resistant pseudomonas aeruginosa

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 1, 2017, Pages

  Oshima, Kazuhiro ^a,b,c   Nakamura, Shigeki ^e   Iwanaga, Naoki ^c   Takemoto, Koji ^f   Miyazaki, Taiga ^b,c   Yanagihara, Kastunori ^d   Miyazaki, Yoshitsugu ^e   Mukae, Hiroshi ^c   Kohno, Shigeru ^c   Izumikawa, Koichi ^b  

^a Leading Program   (Japan)

^b Unit of Molecular Microbiology and Immunology   (Japan)

^c Department of Respiratory Diseases ^*  (Japan)

^d NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^e NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^f DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

High dose; Meropenem; Meropenem resistant Pseudomonas aeruginosa; Pharmacokinetics pharmacodynamics

Indexed keywords

CILASTATIN; MEROPENEM; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COUNT; BACTERIAL VIABILITY; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BRONCHOALVEOLAR LAVAGE FLUID; COLONY FORMING UNIT; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG PROTEIN BINDING; EPITHELIAL LINING FLUID; EXPERIMENTAL PNEUMONIA; FEMALE; HALF LIFE TIME; HISTOPATHOLOGY; HUMAN; INFLAMMATORY CELL; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PNEUMONIA; SURVIVAL RATE; ANIMAL; BIOAVAILABILITY; CYTOLOGY; DISEASE MODEL; DRUG ADMINISTRATION; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; LUNG; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MORTALITY; PNEUMONIA, BACTERIAL; PSEUDOMONAS INFECTIONS; RESPIRATORY MUCOSA; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY MUCOSA; SURVIVAL ANALYSIS; THIENAMYCINS; TREATMENT OUTCOME;

EID: 85009250635     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02056-16     Document Type: Article

References (42)

1. Chalmers JD, Rother C, Salih W, Ewig S. 2014. Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis. Clin Infect Dis 58:330-339. https://doi.org/10.1093/cid/cit734.
2. Tumbarello M, De Pascale G, Trecarichi EM, Spanu T, Antonicelli F, Maviglia R, Pennisi MA, Bello G, Antonelli M. 2013. Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients. Intensive Care Med 39:682-692. https://doi.org/10.1007/s00134-013-2828-9.
3. Kang CI, Kim SH, Kim HB, Park SW, Choe YJ, Oh MD, Kim EC, Choe KW. 2003. Pseudomonas aeruginosa bacteremia: riskfactors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 37:745-751. https://doi.org/10.1086/377200.
4. American Thoracic Society, Infectious Diseases Society of America. 2005. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Re-spir Crit Care Med 171:388-416. https://doi.org/10.1164/rccm.200405-644ST.
5. Solomon SL, Oliver KB. 2014. Antibiotic resistance threats in the United States: stepping back from the brink. Am Fam Physician 89:938-941.
6. Yanagihara K, Kadota J, Aoki N, Matsumoto T, Yoshida M, Yagisawa M, Oguri T, Sato J, Ogasawara K, Wakamura T, Sunakawa K, Watanabe A, Iwata S, Kaku M, Hanaki H, Ohsaki Y, Watari T, Toyoshima E, Takeuchi K, Shiokoshi M, Takeda H, Miki M, Kumagai T, Nakanowatari S, Takahashi H, Utagawa M, Nishiya H, Kawakami S, Kobayashi N, Takasaki J, Mezaki K, Konosaki H, Aoki Y, Yamamoto Y, Shoji M, Goto H, Saraya T, Kurai D, Okazaki M, Niki Y, Yoshida K, Kawana A, Saionji K, Fujikura Y, Miyazawa N, Kudo M, Sato Y, Yamamoto M, Yoshida T, Nakamura M, Tsukada H, et al. 2015. Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of Japanese Society of Che-motherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2010: general view of the pathogens' antibacterial susceptibility. J Infect Chemother 21:410-420. https://doi.org/10.1016/jjiac.2015.02.008.
7. Lee CH, Su TY, Ye JJ, Hsu PC, Kuo AJ, Chia JH, Lee MH. 27 June 2015. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems. J Microbiol Immunol Infect 2015:S1684-1182(15)00767-7. https://doi.org/10.1016/jjmM.2015.06.003.
8. Montero M, Horcajada JP, Sorli L, Alvarez-Lerma F, Grau S, Riu M, Sala M, Knobel H. 2009. Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections. Infection 37: 461-465. https://doi.org/10.1007/s15010-009-8342-x.
9. Luyt CE, Brechot N, Trouillet JL, Chastre J. 2014. Antibiotic stewardship in the intensive care unit. Crit Care 18:480. https://doi.org/10.1186/s13054-014-0480-6.
10. Mac Dougall C, Polk RE. 2005. Antimicrobial stewardship programs in health care systems. Clin Microbiol Rev 18:638-656. https://doi.org/10.1128/CMR.18.4.638-656.2005.
11. Breilh D, Texier-Maugein J, Allaouchiche B, Saux MC, Boselli E. 2013. Carbapenems. J Chemother 25:1-17. https://doi.org/10.1179/1973947812Y.0000000032.
12. Okada K, Kimura T, Mikamo H, Kasahara K, Seki M, Takakura S, Tokimatsu I, Ohmagari N, Takahashi Y, Matsumoto K, Igarashi M, Kobayashi M, Hamada Y, Mochizuki T, Kimura M, Nishi Y, Tanigawara Y, Takesue Y; Japanese Society of Chemotherapy; Japanese Society of Therapeutic Drug Monitoring. 2014. Clinical practice guidelines for therapeutic drug monitoring of arbekacin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother 20:1-5. https://doi.org/10.1016/jjiac.2013.08.008.
13. Canton R, Morosini MI. 2011. Emergence and spread of antibiotic resistance following exposure to antibiotics. FEMS Microbiol Rev 35:977-991. https://doi.org/10.1111/j.1574-6976.2011.00295.x.
14. Li X, Wang L, Zhang XJ, Yang Y, Gong WT, Xu B, Zhu YQ, Liu W. 2014. Evaluation of meropenem regimens suppressing emergence of resistance in Acinetobacter baumannii with human simulated exposure in an in vitro intravenous-infusion hollow-fiber infection model. Antimicrob Agents Chemother 58:6773-6781. https://doi.org/10.1128/AAC.03505-14.
15. Falagas ME, Vardakas KZ, Tsiveriotis KP, Triarides NA, Tansarli GS. 2014. Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections. Int J Antimicrob Agents 44:1-7. https://doi.org/10.1016/j.ijantimicag.2014.01.006.
16. Nicasio AM, Eagye KJ, Nicolau DP, Shore E, Palter M, Pepe J, Kuti JL. 2010. Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. J Crit Care 25:69-77. https://doi.org/10.1016/jjcrc.2009.02.014.
17. Kohno S, Tateda K, Mikamo H, Kadota J, Niki Y, Itamura R. 2015. Efficacy and safety of intravenous sulbactam/ampicillin 3 g 4 times daily in Japanese adults with moderate to severe community-acquired pneumonia: a multicenter, open-label, uncontrolled study. J Infect Che-mother 21:182-188. https://doi.org/10.1016/jjiac.2014.11.006.
18. Ralston SL, Lieberthal AS, Meissner HC, Alverson BK, Baley JE, Gadomski AM, Johnson DW, Light MJ, Maraqa NF, Mendonca EA, Phelan KJ, Zorc JJ, Stanko-Lopp D, Brown MA, Nathanson I, Rosenblum E, Sayles S, III, Hernandez-Cancio S, American Academy of Pediatrics. 2014. Clinical practice guideline: the diagnosis, management, and prevention of bron-chiolitis. Pediatrics 134:e1474-e1502. https://doi.org/10.1542/peds.2014-2742.
19. Blumer JL, Saiman L, Konstan MW, Melnick D. 2005. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Chest 128:2336-2346. https://doi.org/10.1378/chest.128.4.2336.
20. Rodvold KA, George JM, Yoo L. 2011. Penetration ofanti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents. Clin Pharmacokinet 50:637-664. https://doi.org/10.2165/11594090-000000000-00000.
21. Kiem S, Schentag JJ. 2008. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother 52:24-36. https://doi.org/10.1128/AAC.00133-06.
22. Frippiat F, Musuamba FT, Seidel L, Albert A, Denooz R, Charlier C, Van Bambeke F, Wallemacq P, Descy J, Lambermont B, Layios N, Damas P, Moutschen M. 2015. Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study. J Antimicrob Chemother 70:207-216. https://doi.org/10.1093/jac/dku354.
23. Drusano GL. 2003. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 36(Suppl 1):S42-S50. https://doi.org/10.1086/344653.
24. Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. 2003. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol 43:1116-1123. https://doi.org/10.1177/0091270003257225.
25. Drenjancevic D, Vranes J, Bedenic B, Sakic-Zdravcevic K. 2007. In vitro effect of subinhibitory concentrations of ceftazidime and meropenem on the serum sensitivity of Pseudomonas aeruginosa strains. Coll An-tropol 31:221-225.
26. Cuffini AM, Tullio V, Allocco A, Giachino F, Fazari S, Carlone NA. 1993. The entry of meropenem into human macrophages and its immunomodu-lating activity. J Antimicrob Chemother 32:695-703. https://doi.org/10.1093/jac/32.5.695.
27. Yamaguchi K, Ishii Y, Tateda K, Iwata M, Watanabe N, Shinagawa M, Kayaba H, Kimura M, Suwabe A, Kaku M, Abe Y, Kanemitsu K, Taniguchi N, Murakami M, Maesaki S, Kawamura T, Nomura F, Watanabe M, Kanno H, Horiuchi H, Tazawa Y, Kondo S, Misawa S, Takemura H, Nakashima H, Matsuto T, Fujimoto Y, Ishigo S, Gotoh H, Watanabe O, Yagi T, Shimaoka N, Mikamo H, Yamagishi Y, Fujita N, Komori T, Ichiyama S, Kawano S, Nakayama A, Nakamura F, Kohno H, Fukuda S, Kusano N, Nose M, Yokozaki M, Onodera M, Murao K, Negayama K, Nishimiya T, et al. 2014. Nationwide surveillance of parenteral antibiotics containing mero-penem activities against clinically isolated strains in 2012. Jpn J Antibiot 67:73-107. (In Japanese.)
28. Ishikawa K, Hamasuna R, Uehara S, Yasuda M, Yamamoto S, Hayami H, Takahashi S, Matsumoto T, Minamitani S, Kadota J, Iwata S, Kaku M, Watanabe A, Sunakawa K, Sato J, Hanaki H, Tsukamoto T, Kiyota H, Egawa S, Deguchi T, Matsumoto M, Tanaka K, Arakawa S, Fujisawa M, Kumon H, Kobayashi K, Matsubara A, Wakeda H, Amemoto Y, Onodera S, Goto H, Komeda H, Yamashita M, Takenaka T, Fujimoto Y, Tsugawa M, Takahashi Y, Maeda H, Onishi H, Ishitoya S, Nishimura K, Mitsumori K, Ito T, Togo Y, Nakamura I, Ito N, Kanamaru S, Hirose T, Muranaka T, Yamada D, et al. 2015. Japanese nationwide surveillance in 2011 of antibacterial susceptibility patterns of clinical isolates from complicated urinary tract infection cases. J Infect Chemother 21:623-633. https://doi.org/10.1016/j.jiac.2015.05.014.
29. Flamm RK, Nichols WW, Sader HS, Farrell DJ, Jones RN. 2016. In vitro activity of ceftazidime/avibactam against Gram-negative pathogens iso-lated from pneumonia in hospitalised patients, including ventilated patients. Int J Antimicrob Agents 47:235-242. https://doi.org/10.1016/j.ijantimicag.2016.01.004.
30. Flamm RK, Rhomberg PR, Jones RN, Farrell DJ. 2015. In vitro activity of RX-P873 against Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii. Antimicrob Agents Chemother 59:2280-2885. https://doi.org/10.1128/AAC.04840-14.
31. Kanj SS, Whitelaw A, Dowzicky MJ. 2014. In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011. Int J Antimicrob Agents 43:170-178. https://doi.org/10.1016Zj.ijantimicag.2013.10.011.
32. Li Y, Lv Y, Xue F, Zheng B, Liu J, Zhang J. 2015. Antimicrobial resistance surveillance of doripenem in China. J Antibiot 68:496-500. https://doi.org/10.1038/ja.2015.25.
33. Sader HS, Rhomberg PR, Farrell DJ, Jones RN. 2015. Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia. Antimicrob Agents Chemother 59:3263-3270. https://doi.org/10.1128/AAC.04839-14.
34. Tato M, Garcia-Castillo M, Bofarull AM, Canton R, CENIT Study Group. 2015. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Span-ish medical centres: results of the CENIT study. Int J Antimicrob Agents 46:502-510. https://doi.org/10.1016/jjjantimicag.2015.07.004.
35. Harada Y, Morinaga Y, Kaku N, Nakamura S, Uno N, Hasegawa H, Izumikawa K, Kohno S, Yanagihara K. 2014. In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae. Clin Microbiol Infect 20: O831-O839. https://doi.org/10.1111/1469-0691.12677.
36. Nakashima M, Uematsu T, Kanamaru M, Ueno K. 1992. Clinical phase I study of meropenem. Chemotherapy 40(Suppl 1):258-275.
37. Ikawa K, Morikawa N, Urakawa N, Ikeda K, Ohge H, Sueda T. 2007. Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients. J Antimicrob Chemother 60:1395-1397. https://doi.org/10.1093/jac/dkm371.
38. Mattie H, Zhang LC, van Strijen E, Sekh BR, Douwes-Idema AE. 1997. Pharmacokinetic and pharmacodynamic models of the antistaphylococcal effects of meropenem and cloxacillin in vitro and in experimental infection. Antimicrob Agents Chemother 41:2083-2088.
39. Astra Zeneca Pharmaceuticals. 2013. Merrem package insert. Astra Zeneca Pharmaceuticals, Wilmington, DE.
40. Tanaka A, Nakamura S, Seki M, Fukudome K, Iwanaga N, Imamura Y, Miyazaki T, Izumikawa K, Kakeya H, Yanagihara K, Kohno S. 2013. Toll-like receptor 4 agonistic antibody promotes innate immunity against severe pneumonia induced by coinfection with influenza virus and Streptococcus pneumoniae. Clin Vaccine Immunol 20:977-985. https://doi.org/10.1128/CVI.00010-13.
41. Yanagihara K, Seki M, Cheng PW. 2001. Lipopolysaccharide induces mucus cell metaplasia in mouse lung. Am J Respir Cell Mol Biol 24: 66-73. https://doi.org/10.1165/ajrcmb.24.1.4122.
42. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-9th ed. M07-A9. CLSI, Wayne, PA.